Commercialization And Logistics

1. Mitigating Risk In Process Automation 8/18/2023

   Two Chief Technical Officer's for therapeutic organizations cover the various ways in which automation helps to reduce risk and why closing systems and reducing the number of manual manipulations is so critical.

2. BPI Interviews Purification And Pharma Analytics Leader 6/9/2025

   Jean Luo, VP of Purification and Pharma Analytics, discusses innovations in bioprocessing, including the development of dPCR assays, lentiviral titer systems, chromatography resins, and supply chain.

3. Regulatory Compliance And Viral Vectors 11/13/2023

   Hear from experts who detail the specific regulatory challenges for advanced therapies, as well as how the regulatory requirements differ in early research and development in academia and in industrial vector production.

4. CTS DynaCellect Fluidics Demonstration 6/9/2025

   Streamline and customize your cell processing workflow with automated, precise control over fluid movement and transfer parameters.

5. TruBio Software: Performing A Single Pump Calibration 5/19/2025

   Confidently manage your bioprocessing systems with precision and ease by learning how to calibrate a single pump using innovative software, which ensures accurate fluid delivery.

6. Driving Down COGS Audience Q&A 8/18/2023

   Expert panelists provide detailed answers to questions submitted in real time by our registrants providing insightful responses regarding analytical challenges to automation, test automation, and more.

7. Overcoming Capacity Constraints 11/13/2023

   How can CGT biotechs overcome issues such as building an in house facility and ultimately get their therapies to patients.

8. Manufacturing Hurdles With Viral Vectors 11/13/2023

   With a wide range of viral vector-based drugs already approved, viral vectors are expected to remain the primary delivery mechanism for the foreseeable future. However, as the demand for viral vectors increases, addressing the challenges related to their manufacture and scale-up is critical. In this segment, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO share what they consider to be the most difficult challenges in vector development and manufacturing currently.

9. Efficient AAV Purification With AAVx And AAV9 Magnetic Beads 6/30/2025

   Explore an alternative to chromatographic affinity capture that eliminates the need for universal nuclease treatment by utilizing magnetic beads with ligands specific to AAV.

10. Knowledge Culture: Downstream Innovation 6/2/2025

    In this workshop, you’ll learn about various solutions, from cell isolation to cell expansion, that can support autologous and allogeneic cell therapy process needs, digital automation, and mycoplasma testing.